Plasma galectin-3 and heart failure outcomes in MADIT-CRT (Multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy)

Journal of Cardiac Failure

Volumn 20, Issue 11, 2014, Pages 793-799

  Stolen, Craig M ^a   Adourian, Aram ^b   Meyer, Timothy E ^a   Stein, Kenneth M ^a   Solomon, Scott D ^c  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

^b BG Medicine   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

biomarkers; cardiac resynchronization therapy; patient selection; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; GALECTIN 3; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CLINICAL TRIAL; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; MIDDLE AGED; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84908381496     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.07.018     Document Type: Article

References (38)

1. N.C. Henderson, and T. Sethi The regulation of inflammation by galectin-3 Immunol Rev 230 2009 160 171
2. H. Sano, D.K. Hsu, L. Yu, J.R. Apgar, I. Kuwabara, and T. Yamanaka Human galectin-3 is a novel chemoattractant for monocytes and macrophages J Immunol 165 2000 2156 2164
3. L. Yu, W.P. Ruifrok, M. Meissner, E.M. Bos, H. van Goor, and B. Sanjabi Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis Circ Heart Fail 6 2013 107 117
4. L. Calvier, M. Miana, P. Reboul, V. Cachofeiro, E. Martinez-Martinez, and R.A. de Boer Galectin-3 mediates aldosterone-induced vascular fibrosis Arterioscler Thromb Vasc Biol 33 2013 67 75
5. J. Sanchez-Mas, A. Lax, M.C. Asensio-Lopez, M.J. Fernandez-del Palacio, L. Caballero, and I.P. Garrido Galectin-3 expression in cardiac remodeling after myocardial infarction Int J Cardiol 172 2014 e98 e101
6. Y.H. Liu, M. d'Ambrosio, T.D. Liao, H. Peng, N.E. Rhaleb, and U. Sharma N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Am J Physiol Heart Circ Physiol 296 2009 H404 H412
7. U.C. Sharma, S. Pokharel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, and B. Schroen Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
8. R.A. de Boer, D.J. Lok, T. Jaarsma, P. van der Meer, A.A. Voors, and H.L. Hillege Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
9. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 2010 826 832
10. D.J. Lok, P. van der Meer, P.W. de la Porte, E. Lipsic, J. van Wijngaarden, and H.L. Hillege Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 2010 323 328
11. D.J. Lok, S.I. Lok, P.W. Bruggink-André de la Porte, E. Badings, E. Lipsic, and J. van Wijngaarden Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure Clin Res Cardiol 102 2013 103 110
12. K.A. Kortekaas, G.E. Hoogslag, R.A. de Boer, M.M. Dokter, M.I. Versteegh, and J. Braun Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair Eur J Heart Fail 15 2013 1011 1018
13. L. Gullestad, T. Ueland, J. Kjekshus, S.H. Nymo, J. Hulthe, and P. Muntendam Galectin-3 predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure (corona) Eur Heart J 33 2012 2290 2296
14. I.S. Anand, T.S. Rector, M. Kuskowski, A. Adourian, P. Muntendam, and J.N. Cohn Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT Eur J Heart Fail 15 2013 511 518
15. M.R. Bristow, L.A. Saxon, J. Boehmer, S. Krueger, D.A. Kass, and T. de Marco Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 2004 2140 2150
16. J.G. Cleland, J.C. Daubert, E. Erdmann, N. Freemantle, D. Gras, and L. Kappenberger The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 2005 1539 1549
17. A.J. Moss, W.J. Hall, D.S. Cannom, H. Klein, M.W. Brown, and J.P. Daubert Cardiac-resynchronization therapy for the prevention of heart-failure events N Engl J Med 361 2009 1329 1338
18. A.S. Tang, G.A. Wells, M. Talajic, M.O. Arnold, R. Sheldon, and S. Connolly Cardiac-resynchronization therapy for mild-to-moderate heart failure N Engl J Med 363 2010 2385 2395
19. S.D. Solomon, E. Foster, M. Bourgoun, A. Shah, E. Viloria, and M.W. Brown Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: Multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy Circulation 122 2010 985 992
20. A.J. Moss, M.W. Brown, D.S. Cannom, J.P. Daubert, M. Estes, and E. Foster Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol Ann Noninvasive Electrocardiol 10 2005 34 43
21. F.E. Harrell Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis 2001 Springer-Verlag New York
22. S. Durrleman, and R. Simon Flexible regression models with cubic splines Stat Med 8 1989 551 561
23. Y. Sun, and J. Lee Testing independent censoring for longitudinal data Stat Sin 21 2011 1315 1339
24. M.J. Pencina, R.B. d'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
25. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
26. R. Berger, A. Shankar, F. Fruhwald, A. Fahrleitner-Pammer, N. Freemantle, and L. Tavazzi Relationships between cardiac resynchronization therapy and n-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study Eur Heart J 30 2009 2109 2116
27. N. Lopez-Andrès, P. Rossignol, W. Iraqi, R. Fay, J. Nuée, and S. Ghio Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial Eur J Heart Fail 14 2012 74 81
28. V. Kutyifa, A. Kloppe, W. Zareba, S.D. Solomon, S. McNitt, and S. Polonsky The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy J Am Coll Cardiol 61 2013 936 944
29. I. García-Bolao, A. Macías, B. López, A. González, J.J. Gavira, and P. Azcárate A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy J Am Coll Cardiol 47 2006 2335 2337
30. I. García-Bolao, B. López, A. Macías, J.J. Gavira, P. Azcárate, and J. Díez Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy Eur Heart J 29 2008 898 906
31. Y. Sun, and K.T. Weber Infarct scar: a dynamic tissue Cardiovasc Res 46 2000 250 256
32. N.A. Turner, and K.E. Porter Function and fate of myofibroblasts after myocardial infarction Fibrogenesis Tissue Repair 6 2013 5
33. M.A. Konstam, D.G. Kramer, A.R. Patel, M.S. Maron, and J.E. Udelson Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment JACC Cardiovasc Imaging 4 2011 98 108
34. C.M. Orrego, N. Nasir, G.H. Oliveira, J.H. Flores-Arredondo, A.M. Cordero-Reyes, and M. Loebe Cellular evidence of reverse cardiac remodeling induced by cardiac resynchronization therapy Congest Heart Fail 17 2011 140 146
35. C. d'Ascia, A. Cittadini, M.G. Monti, G. Riccio, and L. Saccà Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium Eur Heart J 27 2006 201 206
36. N.L. Anderson, and N.G. Anderson The human plasma proteome: History, character, and diagnostic prospects Mol Cell Proteomics 1 2002 845 867
37. BG Medicine. Galectin-3 assay: instructions for use. Waltham, MA: LAB-0001 R14. 2013.
38. BG Medicine. Internal report. Waltham, MA: LAB-0013-EN rev. 04. 2011.